As the article points out, this could be the "breakout product" stem cells need to overcome resistance (in the U.S. of part of A.) to their widespread use. Imagine the sheer impact of having blood enough to treat all patients who need it in whatever life-saving quantities may be needed, free of potential incompatibility problems.
With stem cells, the potential is seemingly unimited; falling behind on studying and developing that potential cannot be a good idea.
Posts
No comments:
Post a Comment